<?xml version="1.0" encoding="UTF-8"?>
<p>This was an open‐label, single‐center, non‐randomized phase II study. All laboratory tests required to assess eligibility were completed within 7 days prior to the start of treatment. The treatment schedule involved the administration of TMZ (200 mg/m
 <sup>2</sup>) on days 1‐5 every 4 weeks. The RR was evaluated as the primary end‐point, and the PFS, OS, and AEs were evaluated as secondary end‐points. Computed tomography examinations were carried out every two cycles. Adverse events were defined using the Common Terminology Criteria for Adverse Events version 4.0.
</p>
